An adenoviral (AdV)-based vector system is a promising platform for vaccine development
and gene therapy applications. Administration of an AdV vector elicits robust innate …

Introduction Colorectal cancer (CRC) is a devastating disease that affects millions of people
worldwide. Recent research has highlighted the crucial role of the guanylate cyclase-C (GC …

Oncolytic viruses are a promising treatment for patients with high-grade gliomas, but
neutralizing antibodies can limit their efficacy in patients with prior virus exposure or upon …

The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform for
cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer …

Colorectal cancer, especially liver metastasis, is still a challenge worldwide. Traditional
treatment such as surgery, chemotherapy and radiotherapy have been difficult to be further …

The rapid development of nanobiotechnology has enabled progress in therapeutic cancer
vaccines. These vaccines stimulate the host innate immune response by tumor antigens …

Strategies to augment immunity to self/neoantigens expressed by cancers are urgently
needed to expand the proportion of patients benefiting from immunotherapy, particularly for …

Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses
has been explored and transformed into a genetic transfer vehicle. Modification or deletion …

Colorectal cancer remains a major cause of mortality in the USA, despite advances in
prevention and screening. Existing therapies focus primarily on generic treatment such as …

In this editorial, we highlight articles published in this Special Issue of Vaccines on “Cancer
Vaccines and Immunotherapy for Tumor Prevention and Treatment”, recent developments in …